Cite
Patients with metastatic prostate cancer enrolled in phase 1 trials: Outcomes and molecular alterations
MLA
J.P. Armand, et al. “Patients with Metastatic Prostate Cancer Enrolled in Phase 1 Trials: Outcomes and Molecular Alterations.” Annals of Oncology, vol. 27, Oct. 2016, p. vi130. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........a8efd6404571fd2d0873368f9d7af837&authtype=sso&custid=ns315887.
APA
J.P. Armand, E. Castanon Alvarez, J-M. Michot, Eric Angevin, C. Bonnet, J-C. Soria, A. Hollebecque, Y. Loriot, Ratislav Bahleda, Laurence Albiges, Christophe Massard, Aurélien Marabelle, A. Gazzah, Sandrine Aspeslagh, Sophie Postel-Vinay, F. Bigot, & Andreea Varga. (2016). Patients with metastatic prostate cancer enrolled in phase 1 trials: Outcomes and molecular alterations. Annals of Oncology, 27, vi130.
Chicago
J.P. Armand, E. Castanon Alvarez, J-M. Michot, Eric Angevin, C. Bonnet, J-C. Soria, A. Hollebecque, et al. 2016. “Patients with Metastatic Prostate Cancer Enrolled in Phase 1 Trials: Outcomes and Molecular Alterations.” Annals of Oncology 27 (October): vi130. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........a8efd6404571fd2d0873368f9d7af837&authtype=sso&custid=ns315887.